$OSUR News

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OraSure Technologies Receives FDA's Emergency Use Authorization For Its OraQuick Ebola 2.0 Rapid Antigen Test

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies Independent Director Acquires 195% More Stock

OraSure Technologies, Inc. Q1 2026 Earnings Call Summary

OraSure Technologies Q1 Earnings Call Highlights

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies (NASDAQ:OSUR) Q1 2026 Results Meet Revenue Forecast but Losses Widen, Shares Dip

OraSure (OSUR) Q1 2026 Earnings Transcript

OraSure Announces First Quarter 2026 Financial Results

OraSure Technologies Sees Q2 Sales $27.000M-$30.000M vs $29.098M Est

OraSure Technologies Q1 Adj. EPS $(0.24) Misses $(0.23) Estimate, Sales $27.925M Beat $27.707M Estimate

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Why OraSure Technologies (OSUR) Is Back in the Spotlight as Sale Pressure Builds

Altai Capital Presses OraSure Board For Overhaul, Nominates Two Directors

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Defends Strategy Amid Altai Proxy Push; Highlights 2026 Regulatory, Commercial Milestones And Shareholder Value Initiatives

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance